Nifty
:
24286.50
Sensex
:
79986.80
162.65 (0.67%)
545.35 (0.69%)
Nifty
Sensex
:
:
24286.50
79986.80
162.65 (0.67%)
545.35 (0.69%)

Zydus Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 532321 | NSE: ZYDUSLIFE

NSE BSE
1095.25
03-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  1080.90
  •  1115.00
  •  1071.05
  •  1074.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2674685
  •  29372.03
  •  1172.50
  •  567.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 108,114.81
  • 28.01
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 107,778.31
  • 0.28%
  • 5.45

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.98%
  • 0.61%
  • 5.28%
  • FII
  • DII
  • Others
  • 5.72%
  • 12.53%
  • 0.88%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.09
  • 5.54
  • 6.17

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.59
  • 3.70
  • 1.08

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.81
  • 0.75
  • -4.60

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.77
  • 24.19
  • 23.21

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.08
  • 3.33
  • 3.29

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.72
  • 14.50
  • 14.54

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
5,533.80
5,010.60
10.44%
4,505.20
4,257.10
5.83%
4,368.80
4,005.50
9.07%
5,139.60
3,964.30
29.65%
Expenses
3,908.60
3,755.00
4.09%
3,423.40
3,406.30
0.50%
3,304.90
3,319.40
-0.44%
3,634.30
3,239.70
12.18%
EBITDA
1,625.20
1,255.60
29.44%
1,081.80
850.80
27.15%
1,063.90
686.10
55.06%
1,505.30
724.60
107.74%
EBIDTM
29.37%
25.06%
24.01%
19.99%
24.35%
17.13%
29.29%
18.28%
Other Income
161.70
37.80
327.78%
58.30
143.70
-59.43%
136.20
173.60
-21.54%
36.00
174.30
-79.35%
Interest
34.60
27.70
24.91%
19.80
32.80
-39.63%
8.70
35.10
-75.21%
18.10
34.30
-47.23%
Depreciation
205.30
178.60
14.95%
194.80
181.60
7.27%
184.20
181.80
1.32%
179.80
180.70
-0.50%
PBT
1,547.00
485.80
218.44%
925.50
780.10
18.64%
1,007.20
642.80
56.69%
1,329.20
681.00
95.18%
Tax
321.20
137.20
134.11%
213.80
195.20
9.53%
226.40
137.00
65.26%
216.10
118.40
82.52%
PAT
1,225.80
348.60
251.64%
711.70
584.90
21.68%
780.80
505.80
54.37%
1,113.10
562.60
97.85%
PATM
22.15%
6.96%
15.80%
13.74%
17.87%
12.63%
21.66%
14.19%
EPS
11.75
2.93
301.02%
7.80
6.16
26.62%
7.91
5.16
53.29%
10.74
5.06
112.25%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
19,547.40
17,237.40
15,109.90
14,403.50
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
Net Sales Growth
13.40%
14.08%
4.90%
1.06%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
 
Cost Of Goods Sold
6,228.20
5,335.70
4,757.00
4,094.20
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
Gross Profit
13,319.20
11,901.70
10,352.90
10,309.30
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
GP Margin
68.14%
69.05%
68.52%
71.57%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
Total Expenditure
14,271.20
13,665.50
11,935.20
11,018.20
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
Power & Fuel Cost
-
343.50
299.30
231.60
252.90
231.60
211.40
174.50
155.40
145.40
129.70
% Of Sales
-
1.99%
1.98%
1.61%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
Employee Cost
-
2,456.40
2,177.70
2,069.50
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
% Of Sales
-
14.25%
14.41%
14.37%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
Manufacturing Exp.
-
2,639.80
2,272.30
2,271.40
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
% Of Sales
-
15.31%
15.04%
15.77%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
General & Admin Exp.
-
737.70
506.70
444.00
582.60
583.40
398.70
466.00
356.40
326.80
302.70
% Of Sales
-
4.28%
3.35%
3.08%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
Selling & Distn. Exp.
-
1,557.20
1,373.30
1,358.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
% Of Sales
-
9.03%
9.09%
9.43%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
Miscellaneous Exp.
-
595.20
548.90
548.90
525.90
371.20
404.40
502.60
416.10
330.50
980.50
% Of Sales
-
3.45%
3.63%
3.81%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
EBITDA
5,276.20
3,571.90
3,174.70
3,385.30
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
EBITDA Margin
26.99%
20.72%
21.01%
23.50%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
Other Income
392.20
474.60
390.70
47.40
117.10
208.50
133.00
147.10
116.60
57.20
85.90
Interest
81.20
129.90
127.00
158.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
Depreciation
764.10
722.70
713.00
669.60
696.50
598.60
538.80
373.30
292.10
287.30
201.20
PBT
4,808.90
3,193.90
2,725.40
2,604.30
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
Tax
977.50
587.80
511.70
193.60
319.80
530.30
564.40
128.90
177.40
259.40
106.00
Tax Rate
20.33%
22.70%
18.03%
8.07%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
PAT
3,831.40
1,870.30
2,195.40
2,154.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
PAT before Minority Interest
3,718.10
2,001.90
2,326.40
2,205.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
Minority Interest
-113.30
-131.60
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
PAT Margin
19.60%
10.85%
14.53%
14.96%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
PAT Growth
91.39%
-14.81%
1.91%
87.68%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
 
EPS
38.08
18.59
21.82
21.41
11.41
17.91
17.02
14.45
18.79
11.41
7.99

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
17,515.80
16,999.60
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
Share Capital
101.20
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
17,414.60
16,897.20
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
Non-Current Liabilities
-725.00
-193.60
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
Secured Loans
0.00
0.00
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
Unsecured Loans
0.00
362.10
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
Long Term Provisions
271.80
325.00
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
Current Liabilities
5,526.70
7,826.80
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
Trade Payables
2,125.00
2,137.80
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
Other Current Liabilities
1,798.50
1,967.50
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
Short Term Borrowings
1,081.00
3,314.10
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
Short Term Provisions
522.20
407.40
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
Total Liabilities
24,490.00
26,687.00
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
Net Block
11,520.90
12,188.50
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
Gross Block
18,343.80
17,650.90
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
Accumulated Depreciation
6,822.90
5,462.40
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
Non Current Assets
14,477.60
14,438.20
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
Capital Work in Progress
1,200.70
725.90
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
Non Current Investment
927.30
934.80
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
Long Term Loans & Adv.
358.70
369.30
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
Other Non Current Assets
470.00
219.70
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
Current Assets
10,008.20
12,095.20
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
Current Investments
619.30
2,353.20
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
Inventories
3,413.30
3,719.40
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
Sundry Debtors
4,416.80
3,340.30
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
Cash & Bank
573.10
1,106.90
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
Other Current Assets
985.70
229.90
523.90
441.60
1,080.50
1,048.40
348.50
358.90
311.50
323.50
Short Term Loans & Adv.
711.70
1,345.50
741.40
643.90
584.50
527.70
268.50
234.80
240.80
254.90
Net Current Assets
4,481.50
4,268.40
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
Total Assets
24,485.80
26,533.40
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
2,688.80
2,104.50
3,293.90
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
PBT
2,582.70
5,232.30
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
Adjustment
933.90
-2,117.20
1,163.00
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
Changes in Working Capital
-235.80
-336.00
191.10
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
Cash after chg. in Working capital
3,280.80
2,779.10
3,638.90
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-592.00
-674.60
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
Cash From Investing Activity
1,171.20
-1,000.30
-724.60
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
Net Fixed Assets
-669.30
-490.20
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
Net Investments
238.70
1,352.60
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
Others
1,601.80
-1,862.70
-195.30
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
Cash from Financing Activity
-4,400.40
-868.30
-2,547.70
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
Net Cash Inflow / Outflow
-540.40
235.90
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
Opening Cash & Equivalents
1,106.90
888.30
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
Closing Cash & Equivalent
573.10
1,106.90
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
173.08
166.01
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
ROA
7.82%
9.40%
9.66%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
ROE
11.60%
15.51%
18.88%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
ROCE
13.64%
15.30%
14.23%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
Fixed Asset Turnover
1.88
1.69
1.69
0.88
1.05
1.38
1.38
1.76
1.80
1.63
Receivable days
41.75
39.94
42.92
97.49
99.21
83.37
76.72
63.29
56.38
51.71
Inventory Days
38.39
42.95
38.08
70.13
70.33
63.69
59.88
54.52
60.13
63.89
Payable days
145.80
166.64
189.45
64.85
68.81
68.11
74.18
65.30
55.05
49.83
Cash Conversion Cycle
-65.67
-83.76
-108.45
102.77
100.73
78.94
62.42
52.51
61.46
65.78
Total Debt/Equity
0.07
0.25
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
Interest Cover
20.94
23.35
16.11
5.38
13.17
21.87
26.55
40.75
22.29
8.98

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Zydus Lifesciences inks licensing agreement with Dr. Reddy’s Laboratories
    29th Jun 2024, 14:48 PM

    Under the terms of this agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market the product in India

    Read More
  • Zydus Lifesciences gets USFDA’s tentative nod for Azilsartan Medoxomil and Chlorthalidone Tablets
    14th Jun 2024, 14:45 PM

    Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of $77.9 million in the United States

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Theophylline Extended-Release Tablets
    22nd May 2024, 12:40 PM

    The drug will be manufactured at the group’s formulation manufacturing facility in Ahmedabad SEZ, India

    Read More
  • Zydus Lifesciences reports 3- fold jump in Q4 consolidated net profit
    17th May 2024, 16:23 PM

    Total consolidated income of the company increased by 12.71% at Rs 5690.20 crore for Q4FY24

    Read More
  • Zydus Lifesciences - Quarterly Results
    17th May 2024, 15:40 PM

    Read More
  • Zydus Lifesciences’ arm signs exclusive licensing, supply agreement with MSN Laboratories
    17th May 2024, 09:28 AM

    As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Dexamethasone Tablets
    11th May 2024, 15:20 PM

    The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh

    Read More
  • Zydus Lifesciences gets USFDA’s approval for Dapsone Gel
    9th May 2024, 12:46 PM

    Dapsone Gel, 7.5% had annual sales of $35.8 million in the United States

    Read More
  • Zydus Lifesciences’ arm acquires worldwide proprietary rights to Zokinvy
    4th May 2024, 16:06 PM

    Zokinvy is approved in the U.S. (2020), European Union and Great Britain (2022), and Japan (2024) for the treatment of Progeria

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Tretinoin Cream
    26th Apr 2024, 14:24 PM

    The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad, India

    Read More
  • USFDA concludes inspection at Zydus Lifesciences’ Vadodara manufacturing site
    24th Apr 2024, 10:15 AM

    The inspection closed with 10 observations

    Read More
  • Zydus Lifesciences gets nod for new drug application of Desidustat Tablets
    23rd Apr 2024, 14:58 PM

    The company has received approval from National Medical Products Administration of China

    Read More
  • USFDA completes inspection at Zydus Lifesciences’ SEZ Onco Injectable manufacturing plant
    28th Mar 2024, 10:38 AM

    The inspection closed with 4 observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.